Literature DB >> 14705114

Identification of amino-terminally cleaved tau fragments that distinguish progressive supranuclear palsy from corticobasal degeneration.

Tetsuaki Arai1, Kenji Ikeda, Haruhiko Akiyama, Takashi Nonaka, Masato Hasegawa, Koichi Ishiguro, Shuji Iritani, Kuniaki Tsuchiya, Eizo Iseki, Saburo Yagishita, Tatsuro Oda, Akihide Mochizuki.   

Abstract

Progressive supranuclear palsy (PSP) and corticobasal degeneration (CBD) are neurodegenerative diseases that are characterized by intracytoplasmic aggregates of hyperphosphorylated tau with four microtubule-binding repeats. Although PSP and CBD have distinctive pathological features, no biochemical difference in aggregated tau has been identified. In this study, we examined the brains of eight patients with PSP, six patients with CBD, and one atypical case with pathological features of both CBD and PSP. On immunoblots of sarkosyl-insoluble brain extracts, a 33kDa band predominated in the low molecular weight tau fragments in PSP, whereas two closely related bands of approximately 37kDa predominated in CBD. Immunoblots of the atypical case showed both the 33kDa band and the 37kDa doublet. Protein sequencing and immunochemical analyses showed that the 33kDa band and the 37kDa doublet consisted of the carboxyl half of tau with different amino termini. These results suggest that, despite the identical composition of tau isoforms, different proteolytic processing of abnormal tau takes place in these two diseases. Such a biochemical divergence may be related to the neuropathological features of these diseases.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 14705114     DOI: 10.1002/ana.10793

Source DB:  PubMed          Journal:  Ann Neurol        ISSN: 0364-5134            Impact factor:   10.422


  54 in total

1.  Neuropathological features of corticobasal degeneration presenting as corticobasal syndrome or Richardson syndrome.

Authors:  Naomi Kouri; Melissa E Murray; Anhar Hassan; Rosa Rademakers; Ryan J Uitti; Bradley F Boeve; Neill R Graff-Radford; Zbigniew K Wszolek; Irene Litvan; Keith A Josephs; Dennis W Dickson
Journal:  Brain       Date:  2011-09-20       Impact factor: 13.501

2.  Tau Diagnostics and Clinical Studies.

Authors:  Illana Gozes; Günter Höglinger; James P Quinn; Nigel M Hooper; Kina Höglund
Journal:  J Mol Neurosci       Date:  2017-10       Impact factor: 3.444

3.  A novel tau mutation, p.K317N, causes globular glial tauopathy.

Authors:  Pawel Tacik; Michael DeTure; Wen-Lang Lin; Monica Sanchez Contreras; Aleksandra Wojtas; Kelly M Hinkle; Shinsuke Fujioka; Matthew C Baker; Ronald L Walton; Yari Carlomagno; Patricia H Brown; Audrey J Strongosky; Naomi Kouri; Melissa E Murray; Leonard Petrucelli; Keith A Josephs; Rosa Rademakers; Owen A Ross; Zbigniew K Wszolek; Dennis W Dickson
Journal:  Acta Neuropathol       Date:  2015-04-22       Impact factor: 17.088

4.  Is it Useful to Classify PSP and CBD as Different Disorders? Yes.

Authors:  Helen Ling; Antonella Macerollo
Journal:  Mov Disord Clin Pract       Date:  2018-03-06

5.  Is it Useful to Classify Progressive Supranuclear Palsy and Corticobasal Degeneration as Different Disorders? No.

Authors:  Günter U Höglinger
Journal:  Mov Disord Clin Pract       Date:  2018-03-06

Review 6.  Neuropathology of frontotemporal lobar degeneration-tau (FTLD-tau).

Authors:  Dennis W Dickson; Naomi Kouri; Melissa E Murray; Keith A Josephs
Journal:  J Mol Neurosci       Date:  2011-07-01       Impact factor: 3.444

7.  Molecular dissection of TDP-43 proteinopathies.

Authors:  Masato Hasegawa; Takashi Nonaka; Hiroshi Tsuji; Akira Tamaoka; Makiko Yamashita; Fuyuki Kametani; Mari Yoshida; Tetsuaki Arai; Haruhiko Akiyama
Journal:  J Mol Neurosci       Date:  2011-06-16       Impact factor: 3.444

Review 8.  Corticobasal degeneration: a pathologically distinct 4R tauopathy.

Authors:  Naomi Kouri; Jennifer L Whitwell; Keith A Josephs; Rosa Rademakers; Dennis W Dickson
Journal:  Nat Rev Neurol       Date:  2011-04-12       Impact factor: 42.937

9.  Discrepancy between clinical and pathological diagnoses of CBD and PSP.

Authors:  Toshiki Mizuno; Kensuke Shiga; Yuriko Nakata; Junko Nagura; Taizen Nakase; Yoshihiro Ueda; Yoshiaki Takanashi; Kohji Urasaki; Yumiko Oyamada; Shinji Fushiki; Junji Nishikawa; Masahiro Yasuhara; Kenji Nakajima; Masanori Nakagawa
Journal:  J Neurol       Date:  2005-03-09       Impact factor: 4.849

10.  Characterization of alternative isoforms and inclusion body of the TAR DNA-binding protein-43.

Authors:  Yoshinori Nishimoto; Daisuke Ito; Takuya Yagi; Yoshihiro Nihei; Yoshiko Tsunoda; Norihiro Suzuki
Journal:  J Biol Chem       Date:  2009-11-03       Impact factor: 5.157

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.